US OKs PhotoCure's actinic keratosis therapy:
This article was originally published in Clinica
Executive Summary
PhotoCure has gained US approval for its photodynamic therapy for actinic keratosis, a sun-induced, pre-cancerous skin condition. The treatment involves the local application of a methyl aminolevulinate cream - currently called Metvix - and illumination with a proprietary red light source (CureLight/Aktilite) to activate the drug. The US approval is contingent on the FDA's acceptance of a tradename other than Metvix, which is similar to that of another dermatology product. The new tradename is expected in several weeks, said the Oslo, Norway firm. As a result of the approval, PhotoCure is entitled to receive a milestone payment of Euros3m ($3.66m) from Galderma, its sales and marketing partner outside the Nordic region. Metvix is already approved in 18 European countries, New Zealand and Australia.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.